Transgenic mice carrying a tetracycline-inducible, truncated transforming growth factor beta receptor (TβRII)

Genesis (United States)

Volumn 42, Issue 1, 2005, Pages 1-5

  Frugier, Tony ^a   Koishi, Kyoko ^a   Matthaei, Klaus I ^b   McLennan, Ian S ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Biology and Environment   (Australia)

Author keywords

Dominant negative receptor; Doxycycline; Mouse; Neuron; Tetracycline inducible expression; Transforming growth factor beta; Transgenic

Indexed keywords

DNA FRAGMENT; DOXYCYCLINE; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE SILENCING; GENETIC ANALYSIS; MOUSE; NERVE CELL; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 20044377614     PISSN: 1526954X     EISSN: None     Source Type: Journal    
DOI: 10.1002/gene.20115     Document Type: Article

References (19)

1. Baron U, Freundlieb S, Gossen M, Bujard H. 1995. Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 23:3605-3606.
2. Chen J, Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE, Picciotto MR, Duman RS, Nestler EJ. 1998. Transgenic animals with inducible, targeted gene expression in brain. Mol Pharmacol 54:495-503.
3. Dunker N, Krieglstein K. 2002. TGFbeta2 (-/-) TGFbeta3 (-/-) double knockout mice display severe midline fusion defects and early embryonic lethality. Anat Embryol 206:73-83.
4. Evan GI, Lewis GK, Ramsay G, Bishop JM. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-3616.
5. Filvaroff EH, Ebner R, Derynck R. 1994. Inhibition of myogenic differentiation in myoblasts expressing a truncated type II TGF-β receptor. Development 120:1085-1095.
6. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 91:9302-9306.
7. Ishikawa O, Yamakawa O, Yamakage A, LeRoy EC, Trojanowska M. 1990. Persistent effect of TGFbeta1 on extracellular matrix gene expression in human dermal fibroblasts. Biochem Biophys Res Commun 169:232-238.
8. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93:10933-10938.
9. Lawler S, Candia AF, Ebner R, Shum L, Lopez AR, Moses HL, Wright CVE, Derynck R. 1994. The murine type II TGFbeta receptor has a coincident embryonic expression and binding preference for TGFbeta 1. Development 120:165-175.
10. Letterio JJ, Bottinger EP. 1998. TGFbeta knockout and dominant-negative receptor transgenic mice. Miner Electrol Metab 24:161-167.
11. Mansuy IM, Winder DG, Moallem TM, Osman M, Mayford M, Hawkins RD, Kandel ER. 1998. Inducible and reversible gene expression with the rtTA system for the study of memory. Neuron 21:257-265.
12. Massague J, Attisano L, Wrana JL. 1994. The TGFbeta family and its composite receptors. Trends Cell Biol 4:172-178.
13. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. 1996. Control of memory formation through regulated expression of a CaMKII transgene. Science 274:1678-1683.
14. McLennan IS, Koishi K. 2002. The transforming growth factor-betas: multifaceted regulators of the development and maintenance of skeletal muscles, motoneurons and Schwann cells. Int J Dev Biol 46:559-567.
15. McLennan IS, Koishi K, Zhang M, Murakami N. 1998. The non-synaptic expression of transforming growth factor-beta 2 is neurally regulated and varies between skeletal muscle fibre types. Neuroscience 87:845-853.
16. Obberghen-Schilling EV, Roche NS, Flanders KC, Sporn MB, Roberts AB. 1988. Transforming growth factor beta1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263: 7741-7746.
17. Oshima M, Oshima H, Taketo MM. 1996. TGFbeta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179:297-302.
18. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI. 1991. Immunohistochemical localization of TGFbeta1, TGFbeta2, and TGFbeta3 in the mouse embryo-expression patterns suggest multiple roles during embryonic development. J Cell Biol 115:1091-1105.
19. Roberts AB, Sporn MB. 1990. The transforming growth factor-betas. In: Sporn MB, Roberts AB, editors. Handbook of experimental pharmacology. Peptide growth factors and their receptors. Berlin: Springer, p 419-472.